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Monogenic forms of vasculitis are rare but increasingly recognized. Furthermore, genetic
immunodeficiency is increasingly associated with inflammatory immune dysregulatory
features, including vasculitis. This case report describes a child of non-consanguineous
parents who presented with chronic digital vasculitis early in life, is of short stature, has
facial dysmorphia, immunodeficiency (low serum IgA, high serum IgM), recurrent bacterial
infections, lymphoproliferation, absence of detectable serum C1q, and low classical
complement pathway activity. We identified a previously reported de novo heterozygous
pathogenic splice mutation in PIK3R1 (c.1425 + 1G > A), resulting in the skipping of
exon 11 of the p85α subunit of phosphatidylinositol 3-kinase and causing activated
PI3Kδ syndrome type II (APDS2). This explained the phenotype, with the exception of
digital vasculitis and C1q deficiency, which have never been described in association
with APDS2. No mutations were identified in C1QA, B, or C, their promoter regions, or in
any other complement component. Functional studies indicated normal monocytic C1q
production and release, suggesting that the observed C1q deficiency was caused by
peripheral consumption of C1q. Since C1q deficiency has never been associated with
APDS2, we assessed C1q levels in two unrelated patients with genetically confirmed
APDS2 and confirmed C1q deficiency in those two cases as well. This observation
suggests C1q deficiency to be an inherent but previously unrecognized feature of APDS2.
We speculate that the consumption of C1q is driven by increased apoptotic bodies
derived from immune cellular senescence, combined with elevated IgM production
(both inherent features of APDS2). Secondary C1q deficiency in APDS2 may further
contribute to immunodeficiency and could also be associated with inflammatory immune
dysregulatory phenotypes, such as the digital vasculitis observed in our case.
Keywords: digital vasculitis, C1q deficiency, SHORT syndrome, activated PI3Kδ syndrome type 2, hyper-IgM
syndrome, immunodeficiency
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BACKGROUND
The introduction of next-generation genetic sequencing
(NGS) into routine clinical care has resulted in a significant
diagnostic impact in any fields of medicine, including primary
immunodeficiency, autoinflammation, and vasculitis (1). Indeed,
many different forms of monogenic vasculitis are increasingly
described (2–7) and, though rare overall, are important to detect
as targeted treatment is sometimes possible; this is an important
tenet of precision medicine. It is also increasingly recognized
that inflammatory features occur in primary immunodeficiencies
due to immune dysregulation. This poses particular therapeutic
challenges since treatment of these autoinflammatory features
often requires immunosuppression; this is of particular concern
in patients with coexisting immunodeficiency. This clinical
problem is particularly acute in the absence of a confirmed
molecular diagnosis, and this argues strongly for the use of
NGS early in the diagnostic pathway for such patients. Not
only has NGS clearly impacted on the discovery of new genetic
immunological diseases, but it is also revealing patients with
atypical immunophenotypes driven by mutations in known
immunodeficiency genes. Herein, we describe a child of non-
consanguineous parents who presented with digital vasculitis
from early on in life, C1q deficiency, immunodeficiency,
recurrent infections, short stature, and facial dysmorphia. Whole
genome sequencing revealed a previously reported (8–10) de
novo heterozygous pathogenic splice mutation in a mutation
hotspot of PIK3R1 (c.1425 + 1G > A), resulting in the skipping
of exon 11 of the p85α subunit of phosphatidylinositol 3-kinase
and confirming the diagnosis of activated PI3Kδ syndrome type
II (APDS2). This fully explained the phenotype, though with
the exception of C1q deficiency, which has never been described
in association with APDS2. Confirmation of low C1q in two
unrelated cases of APDS2, and functional studies confirming
normal production and release of C1q from monocytes from the
index case, suggested that secondary consumptive C1q deficiency
is an inherent but previously unrecognized feature of APDS2,
which may contribute to immune dysregulation associated with
that primary immunodeficiency.
CASE PRESENTATION
The proband is currently a 17-years-old female of mixed Indian
(mother) and Caucasian (father) ethnicity. Both parents were
well with no past medical history of note, as were her two siblings.
The pedigree is summarized in Figure 1A. She was referred at the
age of 6 years for management and further work up of digital
vasculitis on the background of previously documented C1q
and IgA deficiency. She had spontaneously developed vasculitic
lesions of the fingers, toes, and heels (Figure 1B) at the age
of 6 years, with no obvious infectious, cold-exposure, or other
trigger. Peripheral pulses were intact, blood pressure was normal,
there were no urinary symptoms or any history of hematuria or
proteinuria, and no other clinical features of systemic vasculitis
were present. Her past medical history was remarkable, with
intrauterine growth retardation and short stature: age 17 years;
height 152 cm (second percentile); weight 38.6 Kg (<<0.4th
centile); facial dysmorphia with deep-set eyes, astigmatism
prominent jaw, and unilateral choanal atresia (Figure 1C).
Throughout childhood, multiple significant infections were
documented: frequent (six episodes per year) sinopulmonary
infections starting from the first year of life (presumed bacterial,
but no organism isolated by the local hospital); recurrent (at
least six episodes per year) otitis media with secondary hearing
loss requiring hearing aids; recurrent tonsillitis (number not
specified) responding to antibiotics (but no bacterial cause
reliably documented); bronchiectasis (age 10 years); gingivitis; an
episode of necrotizing cervical lymphadenitis (requiring surgical
drainage and intravenous antibiotics (aged 15 years). There was,
however, no histological evidence of lymphoma. Other medical
issues included gastro-esophageal reflux requiring fundoplication
(age 6 years) and obstructive sleep apnea requiring home-
administered continuous positive airway pressure ventilation
(CPAP; clinical features summarized in Supplemental Table 1).
Laboratory investigations are summarized in
Supplemental Table 1. In summary, these revealed elevation of
acute phase reactants only during episodes of infection, which
normalized in between infections; normal total lymphocyte
count; low CD19 B cell count (0.18 × 109/L); modestly reversed
CD4: CD8 ratio. IgA levels were consistently below the lower
limit of detection and IgM was consistently elevated (3.33 g/L;
reference range [RR] 0.5–2.0). Vaccine responses to C. tetani
and H. influenzae B were normal. Serum C1q levels were below
the limits of the assay: <13 mg/L (RR 50–250), measured on
five separate occasions over ∼10 years; classical complement
pathway activity was reduced (24%; RR >40%, but not absent
as might be expected in primary C1q deficiency); alternative
complement pathway activity was normal (99%, RR >10%).
Anti-C1q antibodies were negative and serum C2, C3c, and C4
levels were normal. Antinuclear antibodies were moderately
positive (1:640); other autoantibodies (including against
double-stranded deoxyribonucleic acid, and antineutrophil
cytoplasmic antibodies) were negative. A screening for Epstein-
Barr virus became positive at the age of 17 years (EBV viral
load 2,180 copies/ml of whole blood), although there were
no clinical features of acute EBV infection; peripheral blood
cytomegalovirus (CMV) viral load was negative. Histology
of cervical lymphadenopathy did not reveal any evidence of
lymphoma, nor any evidence of EBV infection. A full histological
description is provided in Supplemental Table 1.
The clinical diagnosis was therefore that of digital vasculitis
from C1q deficiency (presumed genetic) with concomitant
(and incidental) selective IgA deficiency. Elevated IgM was
initially considered (erroneously, as revealed by genetic testing)
a non-specific inflammatory feature. Treatment focused on the
management of infections with antibiotics and subsequently
antibiotic prophylaxis for infection prevention. Treatment of the
digital vasculitis in the absence of any other organ threatening
vasculitis included corticosteroids (mainly oral prednisolone,
but also high dose intravenous pulsed methylprednisolone
for acute flares), hydroxychloroquine (5–6 mg/kg/day orally),
azathioprine (2 mg/kg/day), and intermittent use of vasodilators
(amlodipine 5 mg/day) to improve digital perfusion. These
treatments resulted in some (albeit temporary) therapeutic relief
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FIGURE 1 | Pedigree and clinical phenotype of proband. (A) Pedigree, with affected individual (the proband) in black and unaffected individuals in white. PIK3R1
genotyping of the pedigree identified a de novo mutation in the proband; WT, wild type. (B) Peripheral vasculitis of digits and heel. (C) Facial gestalt reminiscent of
SHORT syndrome (short stature, hyperextensibility of joints and/or inguinal herniae, ocular depression, rieger anomaly of the eye, and teething problems): ocular
depression, nasal deviation, and prominent mandible present in the proband (see main text and Supplemental Table 1). (D) Sanger sequencing confirmed a
heterozygous splice site G/A mutation (black/green overlapping line) at position c.1425 + 1 of PIK3R1 gene in family member II-2 only. This mutation is absent (single
black line corresponding to wild type “G” allele) in the other family members (I-1, I-2, II-1, and II-3).
from painful digital vasculitis but never fully resolved this chronic
problem. Other treatments and interventions are summarized in
Supplemental Table 1.
Both parents and her two siblings displayed no clinical
features. Baseline laboratory investigations in those individuals
(acute phase reactants; full blood count including differential
white cell count; routine clinical chemistry; C1q, C3, and C4
levels) were normal (Supplemental Table 1). There was no
evidence of IgA deficiency or elevated IgM in either of the
unaffected siblings; immunoglobin levels were not examined in
the parents.
GENETIC TESTING, FUNCTIONAL
STUDIES OF C1Q, AND SUBSEQUENT
CLINICAL PROGRESS
All experimental work was performed with ethical approval
(ethics number: 08H071382) and with written informed consent
from all adult participants, assent (where appropriate) for
children, and parental consent for children. The proband
formally re-consented when she reached the age of 16 years.
Initial targeted genetic testing of the proband undertaken
as part of routine clinical care (prior to the more widespread
introduction of next-generation genetic sequencing) focused on
the C1q deficiency as that aspect of the phenotype seemed
particularly pertinent to work up of the digital vasculitis.
Conventional Sanger sequencing of C1QA, C1QB, and C1QC
was performed, with primers designed using Primer-blast.
Supplemental Table 2 shows the forward and reverse primers
used to probe each exon of these genes as well as the
coverage of primers relative to the start and end position on
chromosome 1 (genome reference consortium human build 38
patch 7; CRCh38.p7). Sanger sequencing did not identify any
mutations in C1QA, C1QB, or C1QC. To further investigate the
possibility of mutations in non-coding regions that may disrupt
RNA transcription (11), complimentary deoxyribonucleic acid
(cDNA) was also sequenced using Sanger sequencing (primers
provided in Supplemental Table 3) with no mutation found
(data not shown). A quantitative polymerase chain reaction
of messenger RNA (mRNA) indicated that mRNA expression
for all C1q genes (primers provided in Supplemental Table 4)
in the proband was 2- to 6-fold higher than in three healthy
controls (data not shown). In summary, these initial genetic
investigations did not reveal any mutation in C1q to account
for the profound and persistent C1q deficiency observed, thus
prompting more detailed studies of leukocyte C1q production
and release.
Frontiers in Immunology | www.frontiersin.org 3 November 2019 | Volume 10 | Article 2589
Hong et al. C1q Deficiency in APDS2
DETECTION OF C1Q PRODUCTION IN
MACROPHAGES AND PERIPHERAL
BLOOD MONONUCLEAR CELLS
C1q is predominantly produced by cells of monocytic lineage,
such as immature dendritic cells and macrophages (12).
Monocytes or monocyte-derived macrophages (MDM) were
stimulated with 200 ng/ml IFN-γ and 10µM dexamethasone for
72 h (see Supplemental Methods). Intracellular C1q staining
of macrophages was clearly demonstrated in the proband and
controls at baseline and following stimulation (Figure 2A).
This observation was confirmed using flow cytometry
(Supplemental Methods), which also demonstrated comparable
intracellular and cell surface C1q staining (Figure 2B) of
monocytes in the proband compared with healthy control.
Lastly, cultured macrophages from the proband released
comparable amounts of C1q into supernatants as healthy
controls (Figure 2C). Taken together with the C1q genotyping
studies, these results indicated that the cause of the C1q
deficiency in the proband was due to peripheral consumption,
rather than a defect of production or release, thus indicating
that genetic screening needed to be extended beyond the
complement system.
WHOLE GENOME SEQUENCING
IDENTIFICATION OF DE NOVO PIK3R1
MUTATION
To further investigate a genetic cause of the atypical clinical
and immunological phenotype, the proband and her parents
were recruited to the Genomics England 100,000 Genomes
Project (protocol version 4, 2017), with written informed consent
from parents and assent from the proband; the full protocol is
available online at https://doi.org/10.6084/m9.figshare.4530893.
v4. Simultaneously, NGS was undertaken using our previously
described targeted gene panel for vasculitis and inflammation
(1) to mitigate against any potential delay in return of results
from whole genome sequencing. Whole genome sequencing
revealed a de novo class five mutation in PIK3R1 in the
proband: (c.1425 + 1G > A), resulting in the skipping of
exon 11 of the p85α subunit of phosphatidylinositol 3-kinase
and confirming the diagnosis of activated PI3Kδ syndrome type
II (APDS2) (13, 14). This explained the phenotype of absent
IgA, elevated IgM, recurrent infections, lymphoproliferation, and
dysmorphic features reminiscent of SHORT syndrome (short
stature, hyperextensibility of joints and/or inguinal herniae,
ocular depression, rieger anomaly of the eye, and teething
FIGURE 2 | Immunofluorescence microscopy of intracellular C1q in M2 macrophages derived from the proband and a healthy control. (A) Immunofluorescent
microscopy images taken, using confocal microscopy (original magnification 63×; Supplemental Methods), of unstimulated and stimulated permeabilized
macrophages (72 h with 10µM of dexamethasone and 200 ng/ml of gamma interferon, IFN-γ) from the proband and a healthy control stained with C1q (green) and
DAPI (blue). (B) Flow cytometry (see Supplemental Methods) demonstrated comparable intracellular and surface C1q staining from a healthy control and the
proband monocytes following stimulation with dexamethasone and IFN-γ for 72 h; FSC-H, forward scatter height. (C) C1q levels in the supernatant of monocyte
derived macrophages (MDM) from the proband and healthy controls before and after stimulation with dexamethasone and IFN-γ for 72 h (as described above).
Cultured macrophages from the proband released comparable amounts of C1q into supernatants as healthy controls. Bar chart indicates mean of duplicate
measurements in proband and three healthy controls; error bars indicate standard error of mean.
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problems), which can also be associated with diabetes and insulin
resistance in APDS2 (8, 15). This mutation was also confirmed
as the only pathogenic mutation found in the proband using
our targeted gene panel (for a full list of genes included, see
Supplemental Table 5), which also confirmed that neither parent
had the mutation. Sanger sequencing was also then used to
further (and definitively) confirm this as a de novo mutation
in the proband and also confirm its absence in the parents
and the two unaffected siblings (Figure 1D). Further in-depth
immunophenotyping of the proband confirmed low levels (for
her age) of naïve T cells and relatively high percentage of memory
CD8 cells, consistent with APDS2 (Supplemental Table 6). C1q
deficiency has never been described in association with APDS2
or APDS1, however. This prompted us to contact the authors
(PO, JML and ON) of a report describing two previous cases of
APDS2 (9), one of whom had the same PIK3R1 c.1425+ 1G> A
mutation as the proband. Serum C1q levels in these two patients
were also found to be low. Patient P1 (Supplemental Table 1)
had a C1q level of 60 mg/L (RR 170–430; measured using
nephelometry) prior to sirolimus treatment. This normalized
transiently to 180 mg/L when it was rechecked after >2 years
sirolimus, but subsequently fell again when measured on two
separate occasions (to 43 and 24 mg/L) despite adequate serum
levels of sirolimus. Patient P2 only had the serum C1q level
measured whilst on long-term sirolimus treatment: C1q level 21.2
mg/L (RR 170–430). These results indicated that consumptive
C1q deficiency may be an integral, but hitherto unrecognized,
feature of ADPS2.
Following the confirmation of APDS2 as the diagnosis, the
proband was commenced on sirolimus (2 mg/m2/day, aiming for
pre-dose serum levels between 8 and 12 ng/ml; level of 14 ng/ml
obtained) and subcutaneous immunoglobin replacement therapy
(hizentra 6 g/week). She remains on antibiotic and anti-fungal
prophylaxis (azithromycin, co-trimoxazole, and fluconazole all
at standard doses) and took hydroxychloroquine 200mg once
daily. Sirolimus was poorly tolerated and stopped after 3 months
due to poor appetite, weight loss, abdominal pain, and oral
ulceration. Consequently, we did not have the opportunity to
measure C1q levels in response to sirolimus. At the time of
writing, she is being worked up for allogeneic hematopoietic
stem cell transplantation (allo-HSCT) (8) since the patient has
declined further experimental targeted treatment with the PI3Kδ
inhibitor, leniolisib (8, 16).
DISCUSSION
In this report, we provide the first description of C1q deficiency
occurring in association with genetically confirmed APDS2
caused by a previously well-described de novo splice mutation
in PIK3R1, c.1425 + 1G > A, which is a mutation hot spot that
accounts for 79% of the 64 patients with APDS2 reported to date
(8). PI3KR1 encodes three protein isoforms: the p85α, p55α, and
p50α regulatory phosphoinositide 3-kinase (PI3K) subunits. The
c.1425 + 1G > A splice site mutation results in skipping of exon
11(delE11) (8, 9, 17), which results in reduction of the normal
regulatory inhibitory binding of mutated p85α subunit protein to
the p110δ subunit. This results in the constitutive hyperactivation
of PI3K (Figure 3) (17) and the clinical phenotype of APDS2 in
humans. As our case illustrates, patients with APDS2 typically
present with recurrent sinopulmonary infections, bronchiectasis
and lymphoproliferation, exhibit hyperactive PI3K signaling, and
have a skewing of CD8+ T cells toward terminally differentiated
senescent effector cells with short telomeres (8, 17). The B cell
immunophenotype includes impaired immunoglobulin class-
switch recombination and impaired B cell memory generation
and function, hypogammaglobulinaemia, elevated IgM, and
a progressive loss of B cells (8). Impaired virus control of
EBV and CMV, lymphoproliferation, and various autoimmune
phenomena including cytopenias, and enteropathy are also well-
described in APDS2 (8). Susceptibility to lymphoid malignancies
are a particular concern for patients with APDS2 and APDS1:
in a recent international systematic review, the overall rate of
malignancy in 243 APDS patients (179 with APDS1 and 64
with APDS2) was 12.8%, with diffuse large B cell lymphoma
being the most common, accounting for 89% of malignancies
in that series (8). Some patients with APDS2 also have features
of SHORT syndrome (short stature, hyperextensibility of joints
and/or inguinal herniae, ocular depression, rieger anomaly of
the eye, and teething problems) (8, 15), compatible with the
dysmorphic features we observed in the proband. Vasculitis has
never been described in APDS2 (although lupus-like features
have) (8), but is almost certainly an autoimmune feature of
APDS2 in the proband, particularly since we recently described
cutaneous vasculitis in a young child with megacephaly driven
by mutation in PTEN, another important gene in the same
pathway (18).
The observation of digital vasculitis occurring in the context
of absent C1q in the proband initially prompted detailed genetic
scrutiny of C1q; however, routine Sanger sequencing and
next generation sequencing (including WGS) excluded any
mutations in C1QA, C1QB, C1QC, their respective promoters,
or in any other complement or complement regulatory
component. Moreover, mRNA expression for each of these
genes was increased in the proband compatible with an
attempt at increased production, as would be seen in peripheral
consumption of C1q. Lastly, our in vitro studies indicated that
monocytes from the proband could produce and release C1q,
all pointing toward peripheral consumption as the cause of
the absent C1q we consistently observed in serum from the
proband. Hitherto, there had been no reports of C1q levels in
patients with any form of APDS; we therefore contacted the
authors of another report of two Spanish patients with APDS2,
one of whom had the same mutation as the proband (9). These
two patients were also found to have low levels of C1q, albeit
to a lesser degree than our proband. Intriguingly, one of their
patients (Spanish case P1, Supplemental Table 1) had modestly
low levels of C1q (60 mg/L; RR 170–430), which increased
transiently to be within the normal range (180 mg/L) when it was
checked ∼2 years after commencing sirolimus, but subsequently
fell again despite adequate serum levels of sirolimus. These
preliminary observations suggest that C1q consumption may
be an inherent but hitherto unrecognized feature of APDS2
and is probably not permanently reversible by inhibiting mTOR
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FIGURE 3 | Proposed mechanism of consumptive C1q deficiency in APDS2.
Mutated p85α subunit (red oval) of the PI3K complex results in impaired
inhibitory contact with the p110δ subunit, with constitutive signaling via the
major molecules downstream of the phosphatidylinositol 3-kinase (PI3K)
complex: PDK1, phosphoinositide-dependent kinase-1; AKT3, AKT
serine/threonine kinase 3; PIP3, phosphatidylinositol (3–5)-trisphosphate;
mTORC, mechanistic target of rapamycin complex. Sirolimus exerts its
therapeutic effect by blocking mTORC (red line) downstream of the activated
PI3K complex; leniolisib directly inhibits the p110δ subunit of the PI3K complex
(see main text).
(Figure 3). Nothing is yet known about C1q levels in APDS1,
although, given the clinical and immunological phenotypic
similarities, this is an area worthy of future study for that
disease as well.
What might be the mechanism of peripheral consumption of
C1q in APDS2? The answer may be suggested by considering
the biology of C1q and its important regulatory role in the
immune system in the context of the immunophenotype driven
by constitutive PI3K activation. C1q is the first recognition
subcomponent of the complement classical pathway (19). It
is a 460 kDa hexameric glycoprotein, which forms a tulip-
like structure, with important pattern recognition functionality,
binding to various ligands includingmicrobial surfaces, apoptotic
cells, IgG and IgM, and phosphatidylserine (PS) present on
apoptotic blebs and CRP, amongst other ligands (19). C1q has
a major role in clearing apoptotic debris, which may otherwise
drive autoimmunity (19). Indeed, genetic C1q deficiency
predisposes to systemic lupus erythematosus (SLE): patients
homozygous for loss of function C1q mutations have at least 90%
risk of developing SLE from early in life (19). SLE is mediated by
autoantibodies targeting self-antigens contained within immune
complexes comprising C1q and apoptotic blebs containing
nuclear antigens. These can form immune complexes that deposit
in tissues, driving inflammation and the various inflammatory
features of SLE (skin rash, light sensitivity, glomerulonephritis,
thrombotic episodes, amongst others). We therefore speculate
that the immunophenotype of APDS2 provides a “perfect storm”
of immune dysregulation for C1q consumption by constitutive
PI3K activation driving increased immune cellular senescence
and increased apoptosis, which, in the face of dysregulated
immunoglobin synthesis and elevated IgM, would result in avid
C1q binding (Figure 3). Therefore, the (likely) consumptive C1q
deficiency we observed in ADPS2 may represent a compensatory
attempt to clear excess apoptotic debris, which, in the face of
elevated IgM, results in avid C1q consumption. C1q is also
highly expressed on B cells and negatively influences B cell
receptor (BCR) signaling to promote tolerance (19). It may
also suppress CD4+ T cell activation and proliferation (20),
suggesting that there could be additional compensatory roles
of C1q in ADPS2 designed to curtail inflammatory sequelae of
constitutive PI3K activation. One limitation of our study is that
we were unable to perform C1q staining from any tissue as this
was not available to us.
This case illustrates that C1q consumption may represent
a novel aspect of the immunophenotype associated with
ADPS2 (and possibly ADPS1 as well) and again illustrates
the power of next-generation sequencing to resolve complex
immunophenotypes to facilitate targeted treatment and genetic
counseling for families. Identification of mutated PIK3R1
in the proband informed the therapeutic approach for this
case; in addition to antibiotic prophylaxis, hydroxychloroquine,
intermittent corticosteroids, and immunoglobin replacement
therapy, sirolimus was added in an attempt to reduce PI3K
activation via inhibition of the mammalian target of rapamycin
complex (mTORC; Figure 3), although the published evidence
for efficacy in ADPS2 for this approach is sparse, with an
ongoing guarded prognosis for lymphoma (8). Sirolimus was
not tolerated by the proband, however, with typical associated
side effects manifesting (21), requiring this to be stopped.
Another therapeutic alternative may be targeted PI3Kδ inhibition
with leniolisib (Figure 3), and this is currently being explored
in an ongoing clinical trial for ADPS (NCT02435173) (8).
At the time of writing, however, the proband is currently
being worked on for allogeneic hematopoietic stem cell
transplantation, which is the only known curative therapeutic
option (8, 22), whilst imminently receiving rituximab for chronic
EBV viremia.
In conclusion, in this case report we illustrate the
utility of whole genome sequencing to resolve a complex
immunophenotype caused by de novo splicing mutation in
PIK3R1, and we highlight consumptive C1q deficiency as a
previously unrecognized component of the immunophenotype
associated with APDS2. Secondly, C1q deficiency in APDS2
may further contribute to immunodeficiency and could
also be associated with inflammatory immune dysregulatory
phenotypes, such as the digital vasculitis observed in our
case. Lastly, identification of C1q deficiency may facilitate
a more rapid diagnosis if found in the context of other
clinical features of APDS2 (such as hypogammaglobulinaemia
or hyper IgM phenotype, short stature, facial dysmorphia
and/or lymphoproliferation) by prompting targeted genetic
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sequencing for this specific immunodeficiency if next-generation
sequencing is not readily available or is associated with long
turnaround times.
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